GHRP-6
Growth-hormone-releasing peptide-6
Overview
GHRP-6 is a synthetic hexapeptide GHSR agonist within the GHRP family, distinguishable from its siblings (GHRP-2, Ipamorelin, Hexarelin) by its particular feature of producing robust appetite stimulation in addition to GH release. The appetite effect comes from GHRP-6's ghrelin-pathway activation at the hypothalamic-arcuate nucleus level, ghrelin is the endogenous appetite-stimulating hormone, and GHSR agonists at higher doses recapitulate part of ghrelin's appetite-driving activity. In research contexts, GHRP-6 is studied both for GH-release pharmacology and for orexigenic (appetite-stimulating) applications, making it the GHRP-family member most relevant to research workflows that want both effects rather than just one. Lyochem supplies GHRP-6 as a lyophilized powder at ≥99.0% HPLC purity. The hexapeptide is straightforward to synthesize and the analytical packet covers peak-integration HPLC plus mass spec. Two standard fill sizes (5 mg and 10 mg) cover typical research workflows. For research workflows specifically studying appetite-pharmacology, GHRP-6 is the most appropriate member of the GHRP family; for cleaner GH-selective work, Ipamorelin is preferred to avoid the appetite-and-cortisol confounders.
Who buys this, and why
GH-axis peptides ship to research labs studying somatotropic-pathway pharmacology, IGF-axis signalling, and pulse vs. sustained-elevation GH biology. Buyers qualifying a new source typically request sequence verification on the first lot, the counter-ion form (acetate by default), and stability data at −20 °C. Blends — the CJC-1295 + Ipamorelin co-formulated lot is the canonical example — are co-lyophilised rather than solution-mixed so the ratio is locked at the lyophilisation step.
Primary buyer fit: academic and contract research laboratories.
Specifications
- CAS
- 87616-84-0
- Appearance
- White lyophilized powder
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 5 mg, 10 mg
- MOQ
- On request
- Lead time
- 10–18 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Counter-ion analysis (acetate vs TFA)
- Stability at −20 °C across 12 months
- Solubility in BAC water / PBS reconstitution
Regulatory note
Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration, and not supplied to compounding pharmacies — Lyochem's GH-axis lots are scoped to research workflows only. Buyers studying somatotropic pharmacology should specify the counter-ion form (acetate by default) and any pulse-vs-sustained study design notes at quote stage.
Frequently asked questions
What distinguishes GHRP-6 from GHRP-2 and Ipamorelin within the GHRP family?▾
GHRP-6's defining feature among GHSR agonists is its substantial appetite-stimulating effect, at typical research doses, GHRP-6 produces measurable orexigenic activity that GHRP-2 (smaller appetite effect) and Ipamorelin (essentially no appetite effect) lack. The appetite stimulation comes from GHRP-6's binding profile at the hypothalamic-arcuate-nucleus GHSR, which is the same receptor that endogenous ghrelin engages to drive hunger signaling. The trade-off is a less GH-selective pharmacological profile compared to Ipamorelin. For research workflows specifically studying appetite pharmacology, GHRP-6 is the most appropriate GHRP-family choice; for clean GH-selective work, Ipamorelin remains the preferred tool.
How is GHRP-6 reconstituted and stored for research workflows?▾
Lyophilized GHRP-6 reconstitutes cleanly in bacteriostatic water for injection (BWFI) for multi-use research stocks or sterile water for injection (SWFI) for single-use preparations. The hexapeptide dissolves within 30-60 seconds with gentle swirl; do not vortex (the foaming entrains air and accelerates surface-mediated aggregation). The reconstituted solution should be aliquoted into single-use volumes immediately and held at -20 °C with strict freeze-thaw management, as with the rest of the GHRP family, freeze-thaw cycling is the dominant in-lab degradation pathway, not slow temperature drift. Working stocks are typically prepared at 1-5 mg/mL; for in vivo administration the working concentration is further diluted to the protocol-specified dose volume.